DataMeds AI Announces U.S. License Agreement for REBOOT GLP-1 Care Platform
DataMeds AI plans to integrate REBOOT Health AI’s licensed care management technology into its Health Lives Here app for patients using GLP-1 receptor agonist medications.
DataMeds AI, Inc. (NASDAQ:MEDS) has announced an exclusive U.S. direct-to-consumer licensing, revenue-sharing and marketing agreement with REBOOT Health AI, Inc. The companies plan to adapt REBOOT’s care management technology for patients taking GLP-1 receptor agonist medications and incorporate it into DataMeds AI’s Health Lives Here mobile application.
Under the agreement, DataMeds AI will work with REBOOT to develop GLP-1 weight care support features within Health Lives Here. The plans include technology integration, pilot programmes and a later commercial launch.
The proposed modules are intended to be offered through monthly subscriptions. Health Lives Here is available on Android and iOS devices and is designed to bring together electronic health records and wearable-device information in a dashboard for monitoring goals and progress.
The agreement covers U.S. direct-to-consumer rights to REBOOT’s proprietary platform, along with revenue sharing for subscriptions connected to the GLP Management Platform. REBOOT’s intellectual property portfolio includes six (6) patents and six (6) patent pending applications.
The patents and applications relate to areas including data-based outcome optimisation, goal progression, personalised goal tracking, methods for reaching goals and AI-supported chronic disease management.
Data Health Partners, Inc., the parent company of REBOOT, is currently involved in litigation with Teladoc Health concerning the intellectual property.
DataMeds AI says the Health Lives Here offering may also provide access to Forzet™, a proprietary medical food intended for the dietary management of muscle loss associated with weight loss therapies.
Corexa Health’s pharmacy and distribution divisions are licensed to dispense and distribute FDA-approved GLP-1 receptor agonist drugs. Users of Health Lives Here can choose their own pharmacy. Tollo Health manufactures medical foods and dietary supplements and intends to develop nutritional support programmes for people taking GLP-1 receptor agonist medications.
DataMeds AI also identifies NFL Alumni Health as a marketing partner connected with the Health Lives Here offering. The company has said it expects the broader model to generate revenue linked to pharmacy dispensing, nutraceutical sales, diagnostic laboratory testing and physician services. Those statements are forward-looking and depend on factors including customer adoption, subscription pricing and the development of the planned services.
DataMeds AI, also known as DataMeds SI and DataMEDS, describes itself as a healthcare company combining Health IT, pharmacy, pharmaceutical-adjacent and telemedicine operations. Its platforms include EinsteinRx™ and the blockchain-enabled PharmacyChain™ system. Its Helomics Corporation subsidiary operates a CLIA-certified laboratory in Pittsburgh.
The company has identified several uncertainties surrounding the project, including the timing and cost of integration, consumer adoption and retention, subscription pricing, the validity and enforceability of the licensed intellectual property, and the outcome of the Teladoc litigation. It also cited regulatory issues affecting the platform, medical foods, dietary supplements and GLP-1 medications, as well as liquidity, capital resources and its ability to fund operations.
DataMeds AI, Inc. announced an exclusive license, revenue sharing and marketing agreement with REBOOT Health AI, Inc. for REBOOT’s direct-to-consumer rights in the United States to its proprietary care management platform. The companies plan to tailor the platform for patients taking GLP-1 receptor agonist medications and integrate it into the Health Lives Here mobile application.
DataMeds AI, Inc. announced the agreement on October 14, 2026. The announcement covers the planned integration and commercial launch of a GLP-1 management platform within the Health Lives Here application.
DataMeds AI, Inc. licensed direct-to-consumer rights in the United States to REBOOT Health AI’s proprietary care management platform. The agreement also covers revenue sharing and marketing, with revenue generated from subscriptions related to the GLP Management Platform to be shared between the companies.
DataMeds AI, Inc. plans to develop and integrate REBOOT’s technology into GLP-1 weight care management support modules within the Health Lives Here app. The company also plans to conduct pilot programmes and launch the platform commercially, although the release says the timing and cost of integration are forward-looking matters.
DataMeds AI, Inc. says the GLP-1 weight care management modules will be offered on a monthly subscription basis through the Health Lives Here app. The app is available for download on Android and iOS devices and is designed to consolidate electronic health records data, integrate wearables data, and provide a dashboard for tracking goals and progress.
DataMeds AI, Inc., doing business as DataMeds SI, is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through Health IT platforms. Its operations include the EinsteinRx™ super intelligence platform, the PharmacyChain™ blockchain-enabled smart contracts platform, Corexa Pharmacy’s dispensing and distribution services, Tollo Health products and a CLIA-certified laboratory operated by Helomics Corporation.
DataMeds AI, Inc. says the Health Lives Here ecosystem can provide access to products including Forzet™, a proprietary medical food for the dietary management of muscle loss associated with weight loss therapies. The company also refers to potential revenue associated with pharmacy dispensing, nutraceutical sales, diagnostic lab testing and physician services, but identifies these as forward-looking expectations.
DataMeds AI, Inc. identifies NFL Alumni Health as a marketing platform, Tollo Health as a provider of medical foods and dietary supplements, and Corexa Health’s pharmacy and distribution divisions as licensed to dispense and distribute FDA-approved GLP-1 receptor agonist drugs. Patients and providers using Health Lives Here are able to choose their own pharmacy.
REBOOT’s patent family includes six (6) patents and six (6) patent pending applications covering areas including data-driven outcomes, goal progression, customised goals, methods for achieving goals and AI-enhanced chronic disease management. The source also states that Data Health Partners, REBOOT’s parent company, is currently in litigation with Teladoc regarding the intellectual property.
DataMeds AI, Inc. says the agreement provides an opportunity to integrate REBOOT’s data-driven, evidence-based outcome optimisation technology with its mobile application. Interim Co-CEO Gerald E. Commissiong said the company expects the agreement to support subscription-based services and revenue associated with pharmacy dispensing, nutraceutical sales, diagnostic lab testing and physician services, while noting that these are forward-looking statements.
DataMeds AI, Inc. identifies uncertainties including consumer adoption and retention, subscription pricing, the validity and enforceability of the licensed patents, the outcome of the litigation with Teladoc Health, and the regulatory status of the platform, medical foods and dietary supplements. The release also refers to the availability, pricing and regulation of GLP-1 medications, the company’s liquidity and capital resources, and its ability to fund operations.
DataMeds AI, Inc. identifies its shares as trading on NASDAQ under the ticker symbol NASDAQ:MEDS. The company is also referred to in the announcement as DataMeds AI, DataMEDS SI and DataMEDS.
DataMeds AI, Inc. says it will work with REBOOT to develop and integrate the technology into the Health Lives Here app, conduct pilot programmes and launch the GLP Management Platform commercially. The source does not provide a specific calendar date for those steps.